Friday, July 10, 2026

pharma · Asthma · Multiple Sclerosis · TEVA

Teva Pharma

Teva Biotech is a pharma organization headquartered in TEL AVIV, DE. It trades on NYSE under ticker TEVA. Primary therapeutic focus areas include Asthma, Multiple Sclerosis, Pain, Crohn's Disease, Seasonal Allergic Rhini

10 Dornierstr., Ulm, Donau, 89079, DE, TEL AVIV HQ
126 Employees
Public company Type
TEVA · NYSE Ticker
Company details
Clinical program

SCE-B

Approved · small molecule · Nocturnal Vasomotor Symptoms

SCE-B for Nocturnal Vasomotor Symptoms is a Approved program (small_molecule) at Teva Pharma GmbH with 1 ClinicalTrials.gov record(s).

← All Teva Pharma GmbH projects Approved small molecule completed

Internal code DR-ENJ-401

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Teva Pharma GmbH
Phase
Approved
Modality
small_molecule
Indication
Nocturnal Vasomotor Symptoms
Status
completed
Trials
1

Clinical trials